journal article·2026-03Open access

Elevated interstitial fluid pressure promotes spheroid growth and reduces CAR-T therapeutic efficacy in solid tumors

Pilar Alamán-Díez, Silvia Ferrer-Royo, Carmen Oñate Salafranca, Pablo Martín Compaired, Patricia Balsas, Julián Pardo, José Manuel García-Aznar, Alejandra González-Loyola

Acta Biomaterialia· Volume 213

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest solid tumors and is characterized by aggressive progression, a dense tumor microenvironment (TME), and resistance to conventional therapies. Among the barriers to effective treatments, the presence of elevated interstitial fluid pressure (IFP) may be important for drug penetration and immune cell infiltration. In this work, we present an innovative 3D microfluidic PDAC-on-a-chip that allows the application of IFP in a cell chamber to simulate the TME and evaluate the therapeutic efficacy of CAR-T cells engineered against the receptor EGFR expressed in tumor cells. Elevated IFP was associated with increased tumor spheroid growth, reduced caspase activation and decreased actin remodeling, indicating enhanced tumor resistance. CAR-T cells effectively targeted and eliminated tumor cells in 2D and 3D coculture models under normal pressure conditions. However, under high IFP, CAR-T-mediated cytotoxicity was impaired, indicating that some of the low efficacy of CAR-T cell therapy against solid tumors might be derived from IFP. These results highlight the importance of the mechanoenvironment in limiting the efficacy of current immunotherapies. Our model, which incorporates an IFP component, serves as a realistic preclinical platform for testing antitumor therapies in solid tumors. Statement of Significance In this work, we present an innovative 3D pancreatic tumor-on-a-chip model that incorporates interstitial fluid pressure (IFP), which is a key mechanical component of solid tumors. Using this platform, we discovered that IFP enhances tumor proliferation whilst diminishing immunotherapy efficacy. This indicates the important role of mechanical pressure in limiting immune cell function in solid tumors. Our model is a valuable preclinical platform for investigating the efficacy of anti-tumor therapies and supports the development of strategies to overcome mechanical resistance and enhance therapy efficacy in solid tumors, such as pancreatic cancer.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: 3D Printing in Biomedical Research · CAR-T cell therapy research · Cellular Mechanics and Interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (86)

Show source-provided references
1. Epidemiology of pancreatic cancer: global trends, etiology and risk factors10.14740/wjon1166 ↗
2. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States10.1158/0008-5472.CAN-14-0155 ↗
3. The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities10.1038/s41571-020-0363-5 ↗
4. A new era: tumor microenvironment in chemoresistance of pancreatic cancer10.26502/jcsct.5079146 ↗
5. Gaps and opportunities in the diagnosis and treatment of pancreatic cancer10.3390/cancers15235577 ↗
6. Pancreatic adenocarcinoma management10.1200/OP.22.00328 ↗
7. Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside10.1016/j.trecan.2018.02.005 ↗
8. Mechanotransduction in tumor dynamics modeling10.1016/j.plrev.2023.01.017 ↗
9. Hypoxia as a driver of resistance to immunotherapy10.1016/j.drup.2021.100787 ↗
10. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches10.1186/s13014-019-1345-6 ↗
11. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma10.1016/j.ccr.2012.01.007 ↗
12. Interstitial pressure in pancreatic ductal adenocarcinoma is dominated by a gel-fluid phase10.1016/j.bpj.2016.03.040 ↗
13. Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications10.1186/s40164-024-00591-7 ↗
14. Solid stress inhibits the growth of multicellular tumor spheroids10.1038/nbt0897-778 ↗
15. Micro-environmental mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells10.1371/journal.pone.0004632 ↗
16. Isotropic stress reduces cell proliferation in tumor spheroids10.1088/1367-2630/14/5/055008 ↗
17. Compressive stress inhibits proliferation in tumor spheroids through a volume limitation10.1016/j.bpj.2014.08.031 ↗
18. Quantitative cell-based model predicts mechanical stress response of growing tumor spheroids over various growth conditions and cell lines10.1371/journal.pcbi.1006273 ↗
19. Extracellular matrix density regulates the formation of tumour spheroids through cell migration10.1371/journal.pcbi.1008764 ↗
20. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure10.1016/j.ccr.2014.06.003 ↗
21. Intratumor heterogeneity in interstitial fluid pressure in cervical and pancreatic carcinoma xenografts10.1016/j.tranon.2019.05.012 ↗
22. Microfluidic studies of hydrostatic pressure-enhanced doxorubicin resistance in human breast cancer cells10.1039/D0LC01103G ↗
23. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival10.1016/j.ccr.2014.04.005 ↗
24. Translational advances in pancreatic ductal adenocarcinoma therapy10.1038/s43018-022-00349-2 ↗
25. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S131310.1200/JCO.18.01295 ↗
26. CAR-T cell therapy: current limitations and potential strategies10.1038/s41408-021-00459-7 ↗
27. CAR-T cells are more affected than T lymphocytes by mechanical constraints: A microfluidic-based approach10.1016/j.lfs.2024.123335 ↗
28. Antigen receptor regulate receptor expression and10.3390/cells9051182 ↗
29. Current approaches to increase CAR T cell potency in solid tumors: Targeting the tumor microenvironment10.1186/s40425-017-0230-9 ↗
30. CAR T cells in solid tumors: challenges and opportunities10.1186/s13287-020-02128-1 ↗
31. Rationally designed approaches to augment CAR-T therapy for solid tumor treatment
32. Chimeric antigen receptor T cell therapy for pancreatic cancer: A review of current evidence10.3390/cells13010101 ↗
33. Mesothelin CAR T cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma10.1158/1078-0432.CCR-23-3841 ↗
34. Muc16CD is a novel CAR T cell target antigen for the treatment of pancreatic cancer
35. Systematic review on CAR-T cell clinical trials up to 2022: Academic center input10.3390/cancers15041003 ↗
36. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells10.2119/molmed.2011.00493 ↗
37. Epidermal growth factor receptor cell proliferation signaling pathways10.3390/cancers9050052 ↗
38. High-Throughput cancer cell sphere formation for characterizing the efficacy of photo dynamic therapy in 3D cell cultures
39. Microfluidic assay for simultaneous culture of multiple cell types on surfaces or within hydrogels10.1038/nprot.2012.051 ↗
40. Polydopamine interfacial coating for stable tumor-on-a-chip models: application for pancreatic ductal adenocarcinoma10.1021/acs.biomac.4c00551 ↗
41. Collagen-laponite nanoclay hydrogels for tumor spheroid growth10.1021/acs.biomac.3c00257 ↗
42. From individual to collective 3D cancer dissemination: roles of collagen concentration and TGF-β10.1038/s41598-018-30683-4 ↗
43. Increased extracellular pressure stimulates tumor proliferation by a mechanosensitive calcium channel and PKC-β10.1016/j.molonc.2014.10.008 ↗
44. Molecular cancer cell responses to solid compressive stress and interstitial fluid pressure10.1002/cm.21680 ↗
45. Engineering CAR-T cells for improved function against solid tumors10.3389/fimmu.2018.02493 ↗
46. Cellular memory function from 3D to 2D: Three-dimensional high density collagen microfiber cultures induce their resistance to reactive oxygen species
47. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma10.4161/cbt.10.6.12532 ↗
48. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained10.1038/srep19103 ↗
49. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours10.1038/s41586-022-04585-5 ↗
50. The interferon-γ receptor pathway: a new way to regulate CAR T cell-solid tumor cell adhesion10.1038/s41392-022-01165-x ↗
51. Exhaustion of CAR T cells: potential causes and solutions10.1186/s12967-022-03442-3 ↗
52. TIM3 comes of age as an inhibitory receptor10.1038/s41577-019-0224-6 ↗
53. PD-1 and LAG-3: synergistic fostering of T cell exhaustion10.1038/s41392-024-02000-1 ↗
54. The extracellular matrix and pancreatic cancer: a complex relationship10.3390/cancers10090316 ↗
55. Pancreatic cancer: Stroma and its current and emerging targeted therapies10.1016/j.canlet.2016.12.035 ↗
56. Interstitial fluid pressure as an emerging biomarker in solid tumors
57. Three-dimensional culture and clinical drug responses of a highly metastatic human ovarian cancer HO-8910PM cells in nanofibrous microenvironments of three hydrogel biomaterials10.1186/s12951-020-00646-x ↗
58. Collagen-based three-dimensional culture microenvironment promotes epithelial to mesenchymal transition and drug resistance of human ovarian cancer in vitro10.1039/C7RA13742G ↗
59. Role of c-MET inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells10.3390/cancers11050638 ↗
60. Substantial expression of mature elastin in arterial constructs10.1073/pnas.1017834108 ↗
61. 3D collagen fibrillar microstructure guides pancreatic cancer cell phenotype and serves as a critical design parameter for phenotypic models of EMT10.1371/journal.pone.0188870 ↗
62. KRAS: feeding pancreatic cancer proliferation10.1016/j.tibs.2013.12.004 ↗
63. Ischemic perfusion radiomics: assessing neurological impairment in acute ischemic stroke10.3389/fneur.2024.1441055 ↗
64. The epidermal growth factor10.1006/cbir.1995.1086 ↗
65. Epidermal growth factor receptor–related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells10.1158/0008-5472.CAN-04-3654 ↗
66. High interstitial fluid pressure promotes tumor cell proliferation and invasion in oral squamous cell carcinoma10.3892/ijmm.2013.1496 ↗
67. Regulation of cell cycle progression by cell–cell and cell–matrix forces10.1038/s41556-018-0107-2 ↗
68. Mechanical signaling through the cytoskeleton regulates cell proliferation by coordinated focal adhesion and rho gtpase signaling10.1242/jcs.067009 ↗
69. Fluid-sensitive migration mechanisms predict association between metastasis and high interstitial fluid pressure in pancreatic cancer10.1016/j.jbiomech.2022.111362 ↗
70. Migration dynamics of breast cancer cells in a tunable 3D interstitial flow chamber10.1039/c1ib00128k ↗
71. Cell therapies in the clinic10.1002/btm2.10214 ↗
72. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors10.1016/j.lfs.2023.122381 ↗
73. Systematic review of available CAR-T cell trials around the world10.3390/cancers14112667 ↗
74. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial10.1016/j.jcyt.2020.04.088 ↗
75. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors10.1038/s41423-024-01207-0 ↗
76. CXCL12 (SDF-1α) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells10.1084/jem.20080730 ↗
77. CAR T cell locomotion in solid tumor microenvironment10.3390/cells11121974 ↗
78. CAR T cell therapy in solid tumors: A review of current clinical trials10.1002/jha2.356 ↗
79. Tumor-associated extracellular matrix obstacles for CAR-T cell therapy: approaches to overcoming10.3390/curroncol32020079 ↗
80. Pressure increases PD-L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti-ROR1 CAR T cell-mediated cytotoxicity10.1038/s41598-022-10905-6 ↗
81. Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma10.1053/j.gastro.2016.03.040 ↗
82. Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics10.1593/neo.09554 ↗
83. The extracellular matrix modulates the hallmarks of cancer10.15252/embr.201439246 ↗
84. Defining the role of solid stress and matrix stiffness in cancer cell proliferation and metastasis10.3389/fonc.2018.00055 ↗
85. Microfluidics and nanofluidics for immunotherapy10.1063/5.0281840 ↗
86. Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis10.2217/14796694.4.6.793 ↗